Cargando…
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation
Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD), leading to earlier age of clinical onset and exacerbating pathologies. There is a critical need to identify protective targets. Recently, a rare APOE variant, APOE3-R136S (Christchurch), was fou...
Autores principales: | Nelson, Maxine R., Liu, Peng, Agrawal, Ayushi, Yip, Oscar, Blumenfeld, Jessica, Traglia, Michela, Kim, Min Joo, Koutsodendris, Nicole, Rao, Antara, Grone, Brian, Hao, Yanxia, Yoon, Seo Yeon, Xu, Qin, De Leon, Samuel, Choenyi, Tenzing, Thomas, Reuben, Lopera, Francisco, Quiroz, Yakeel T., Arboleda-Velasquez, Joseph F., Reiman, Eric M., Mahley, Robert W., Huang, Yadong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689245/ https://www.ncbi.nlm.nih.gov/pubmed/37957317 http://dx.doi.org/10.1038/s41593-023-01480-8 |
Ejemplares similares
-
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
por: Koutsodendris, Nicole, et al.
Publicado: (2023) -
Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia
por: Sepulveda-Falla, Diego, et al.
Publicado: (2022) -
APOE4/4 is linked to damaging lipid droplets in Alzheimer’s microglia
por: Haney, Michael S., et al.
Publicado: (2023) -
Resistance to autosomal dominant Alzheimer’s in an APOE3-Christchurch homozygote: a case report
por: Arboleda-Velasquez, Joseph F., et al.
Publicado: (2019) -
Cognitive performance in asymptomatic carriers of mutations R1031C and R141C in CADASIL
por: Zuluaga-Castaño, Yesica, et al.
Publicado: (2018)